



Published in final edited form as:

Bioorg Med Chem. 2010 November 15; 18(22): 7746–7752. doi:10.1016/j.bmc.2010.04.005.

## A collection of caged compounds for probing roles of local translation in neurobiology

Oleg Sadovski<sup>1</sup>, Anna S. I. Jaikaran<sup>1</sup>, Subhas Samanta<sup>1</sup>, Marc R. Fabian<sup>2</sup>, Ryan J. O. Dowling<sup>2</sup>, Nahum Sonenberg<sup>2</sup>, and G. Andrew Woolley<sup>1</sup>

<sup>1</sup> Department of Chemistry, University of Toronto, 80 St. George ST., Toronto, ON Canada, M5S 3H6

<sup>2</sup> Department of Biochemistry, McGill University, Montreal QC Canada H3G 1Y6

### Abstract

Spatially localized translation plays a vital role in the normal functioning of neuronal systems and is widely believed to be involved in both learning and memory formation. It is of central interest to understand both the phenomenon and molecular mechanisms of local translation using new tools and approaches. Caged compounds can, in principle, be used as tools to investigate local translation since optical activation of bioactive molecules can achieve both spatial and temporal resolution on the micron scale and on the order of seconds or less, respectively. Successful caging of bioactive molecules requires the identification of key functional groups in appropriate molecules and the introduction of a suitable caging moiety. Here we present the design, synthesis and testing of a collection of three caged compounds: anisomycin caged with a diethylaminocoumarin moiety and dimethoxynitrobenzyl caged versions of 4E-BP and rapamycin. Whereas caged anisomycin can be used to control general translation, caged 4E-BP serves as a probe of cap-dependent translation initiation and caged rapamycin serves as a probe of the role of mTORC1 in translation initiation. *In vitro* translation assays demonstrate that these caging strategies, in combination with the aforementioned compounds, are effective for optical control making it likely that such strategies can successfully be employed in the study of local translation in living systems.

### Introduction

Spatial and temporal control of protein synthesis (translation) plays a central role in the neural processes that underlie learning and memory (for reviews see<sup>1–7</sup>). However, key questions remain unresolved; *e.g.*, does translation occur only in a stimulated dendritic spine or does it occur elsewhere, and are proteins targeted to that spine? In addition to establishing functional correlates of changes in local translation, one often wishes to probe the molecular mechanisms involved. *i.e.*, *how* does synaptic activity leading to long term potentiation (LTP) trigger translation of specific mRNAs in neurons? Is synthesis cap-dependent or is a cap-independent process involved (*e.g.*<sup>8</sup>)? Does signaling occur through the mTORC1 pathway (a central regulator of translation) or via other signaling cascades (*e.g.*<sup>9</sup>)? Answering such questions requires tools to dissect the regulation of local translation at a single synapse (length scale of ~1  $\mu\text{m}$ ) on the timescale of < 1 min. Such tools could

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

contribute substantially to the fundamental understanding of a variety of important neuronal processes.

Biochemical techniques for manipulating translation have been instrumental in establishing the connection between protein synthesis and development, learning and memory. In general, tools fall into two broad groups: (i) specific small molecule inhibitors and (ii) genetic approaches (e.g. overexpression, knock-outs, etc.). A variety of small molecules are known to inhibit eukaryotic translation. These include emetine, puromycin, anisomycin and cycloheximide. These inhibitors act primarily at the ribosome, preventing peptide bond formation, tRNA binding, or protein elongation<sup>10</sup>; however, additional small molecule inhibitors that target other steps in protein synthesis, including translation initiation, are currently under development<sup>11–13</sup>. These small molecules are generally cell permeable but wash-in and wash-out are not very rapid and, although spatially restricted perfusion has been attempted (e.g.<sup>14</sup>), these drugs are difficult to localize with confidence within micron sized areas.

Genetic approaches have also been used to alter translational efficiency by manipulating components of the protein synthesis machinery (e.g.<sup>15, 16</sup>). While such approaches offer insights into the roles of specific proteins, as opposed to the all-or-none translational response in studies using general protein-synthesis inhibitors, they usually target global neuronal protein synthesis. With conditional control (e.g. using the CreER/loxP or DICE-K system) with cell type specific promoters, some degree of spatiotemporal control can be achieved as has been demonstrated in studies of hippocampal synaptic pathway function (e.g.<sup>17</sup>). Nevertheless, cell-based studies using these strategies may be difficult to interpret, particularly if the biological event under study is relatively fast (seconds/minutes) (e.g. LTP) or has a complex spatial dependence.

Photo-control, in which light is used to directly control a biochemical process, offers the possibility of rapid, spatially localized, external control. Caged compounds (compounds in which a light pulse is used to remove a protecting group and thereby render the molecule bioactive) already enjoy wide use in neurobiology<sup>18</sup>. Caged glutamate, in particular, has been used very successfully in studies of neural function including LTP<sup>19</sup>. In pioneering work, Dore, Schuman and colleagues designed and synthesised a caged version of anisomycin, a protein synthesis inhibitor that functions at the level of the ribosome<sup>20</sup>.

We report here the design, synthesis, and *in vitro* evaluation of a collection of three new caged compounds that permit the photo-control of different molecular steps involved in protein synthesis: (i) a diethylaminocoumarin-caged anisomycin derivative that extends the work of Goard et al.; (ii) a caged 4E-BP peptide that permits selective control of cap-dependent versus cap independent modes of translation initiation and (iii) a caged rapamycin derivative that enables probing of the role of the mTORC1 pathway in regulating local translation.

## Materials and Methods

### DEAC-caged anisomycin (*N*-([7-*N,N*-diethylaminocoumarin-4-yl]methyloxycarbonyl)anisomycin)

To a solution of 15 mg (0.06 mmol) of 7-(diethylamino)-4-(hydroxymethyl)-2*H*-chromen-2-one (prepared exactly as described<sup>21</sup>), in dry acetonitrile was added 12 mg (0.06 mmol) 4-nitrophenyl chloroformate and the solution was stirred for 7h at room temperature under argon. Then 10 mg (0.08 mmol) of 4-dimethylaminopyridine and 10 mg (0.038 mmol) of anisomycin (AG Scientific) was added and the solution was stirred overnight. The reaction was quenched with 3–4 vol 15% citric acid, and extracted with chloroform. The product was

purified by HPLC using a Zorbax SB-C18 column (Chromatographic Specialties Inc.) using isocratic methanol/water 70/30 conditions with a flow rate of 5 mL/min. The product eluted at 13.4 min. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, 1.3:1 mixture of conformational isomers) δ 7.41 (d, *J* = 9.0 Hz, 1H), 7.00 and 6.89 (d, *J* = 8.0 Hz, 2H), 6.72 (d, *J* = 8.0 Hz, 2H), 6.67-6.60 (m, 2H), 6.46 (s, 1H), 5.98 and 5.92 (s, 2H), 5.26 and 5.13 (AB q, 2H), 4.35-4.28 (m, 1H), 4.02 and 3.90 (br s, 1H), 3.65 and 3.60 (s, 3H), 3.50-3.47 (m, 1H), 3.39 (q, *J* = 7.0 Hz, 4H), 3.25-3.08 (m, 1H), 2.92-2.87 (m, 1H), 2.70 (t, *J* = 13.2 Hz, 1H), 1.99 and 1.95 (s, 3H), 1.09 (t, *J* = 7.0 Hz, 6H); ESI-HRMS:(C<sub>29</sub>H<sub>35</sub>N<sub>2</sub>O<sub>8</sub>)(MH<sup>+</sup>), calcd 539.2387, found 539.2396. Uncaging was tested by exposing DEAC-caged anisomycin solutions in 50 mM HEPES buffer pH 7.0 with 5% methanol for solubility to light from a 405 nm high intensity LED (Super Bright LEDs Inc. St. Louis Missouri, Model RL5-UV2030 (405 nm; ~20 mW/cm<sup>2</sup>)). Disappearance of caged anisomycin and appearance of anisomycin were followed by HPLC (Zorbax SB-C18 column acetonitrile/water 60/40 (+0.1% trifluoroacetic acid) for caged anisomycin (eluted at 22 min (detect at 380 nm); acetonitrile/water 35/65 (+0.1% trifluoroacetic acid) for anisomycin (eluted at 9.3 min (detect at 225 nm)) and ESI-HRMS: (C<sub>14</sub>H<sub>20</sub>NO<sub>4</sub>)(MH<sup>+</sup>), calcd 266.1386, found 266.1393

**4E-BP peptides**—Fmoc protected amino acids, Rink amide resin and HBTU were obtained from Anaspec Inc. Preparation of Fmoc-Tyr(O-(4,5-dimethoxy-2-nitrobenzyl))-OH was carried out as described previously<sup>22</sup>. Dimethoxy-2-nitrobenzyl bromide was prepared from veratraldehyde as described<sup>23, 24</sup>. Peptides were prepared using standard Fmoc-based solid-phase peptide synthesis in a microwave peptide synthesizer (CEM Corp.). After synthesis, peptides were HPLC purified using a Zorbax SB-C18 column (Chromatographic Specialties Inc.) using a linear gradient of 5–60% acetonitrile/water containing 0.1% trifluoroacetic acid in 20 minutes was used with a flow rate of 2 mL/min. Peptide composition was confirmed by ESI-MS. 4E-BP1a caged: PGGARIY(dmnb)DRKFLMAibAibRNAPVAKAPP; calcd: 3003.8 found: 3002.7. Uncaging was tested by exposing peptide solutions in water to light from a 365 nm high intensity LED (Opto Technology, Inc., Wheeling, IL, Model OTLH-0480-UV (365 nm, ~20 mW/cm<sup>2</sup>) and following conversion using ESI-MS (uncaged PGGARIYDRKFLMAibAibRNAPVAKAPP) calcd: 2808.34 found: 2807.6.

### Caged rapamycin (7-demethoxy-7-dimethoxy-2-nitrobenzyloxy-rapamycin)

Rapamycin (LC Laboratories, Woburn, MA) (100 mg, 0.110 mmol) was dissolved in dry dichloromethane (3 mL) at -40°C under argon then 100 μL trifluoroacetic acid was added and the solution was stirred for 10 min essentially as described<sup>25</sup>. Ten equivalents of dimethoxy-2-nitrobenzyl alcohol (prepared from veratraldehyde as described<sup>23, 24</sup>) were added and the solution stirred for 1 h at -40°C. The mixture was then extracted with 5% aqueous sodium bicarbonate and dried over anhydrous sodium sulphate. The product was purified by preparative HPLC using a Zorbax SB-C18 column 9.4x25cm (Chromatographic Specialties Inc.) using isocratic methanol/water 85/15 conditions with 0.1 % acetic acid and a flow rate of 5 mL/min (eluted 10 min) followed by a second HPLC step using acetonitrile/water 80/20 Zorbax SB-C18 4.5x25 cm 2 mL/min (eluted at 4.5 min). (Yield 11 mg, ~10%); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)(mixture of trans/cis conformational isomers; data for major isomer) δ 7.71 (s, 1 H, DMNB Ar H-6'), 7.54 (s, 1 H, DMNB Ar H-3'), 6.39-6.32 (m, 1 H), 6.22-6.09 (m, 2 H), 6.02-6.00 (m, 1 H), 5.60-5.50 (m, 1 H), 5.50-5.35 (m, 2 H), 5.35-5.27 (m, 1H), 5.25-5.1 (m, 1 H), 4.72 (s, 1 H, OH-13), 4.35-4.25 (m, 2 H (CH<sub>2</sub> on DMNB)), 4.18 (1 H, H-28, indicating C7-*S* epimer), 3.99 (s, 3H, CH<sub>3</sub>O on DMNB), 3.94 (s, 3H, CH<sub>3</sub>O on DMNB) 3.90-3.85 (m, 1 H), 3.7 (s, 1 H, H-29), 3.7 (m, 1 H), 3.41 (s, 3 H), 3.34 (s, 3 H), 2.94 (m, 1 H), 2.64 (d, 2 H), 1.75 (s, 3 H), 1.40-0.83 (set of broad unresolved peaks, similar to rapamycin) (note singlet at 3.14 ppm (C7-methoxy in rapamycin is not present as expected). ESI-HRMS:(C<sub>59</sub>H<sub>86</sub>N<sub>2</sub>O<sub>17</sub>Na)(MNa<sup>+</sup>), calcd 1117.5819, found

1117.5822. UV-Vis (MeOH)  $\lambda_{\max}$  263, 274, 287, 350 nm. Uncaging was tested by exposing DMNB-caged rapamycin solutions in water with 50% methanol for solubility to light from a 365 nm high intensity LED (Opto Technology, Inc., Wheeling, IL, Model OTLH-0480-UV (365 nm, ~20 mW/cm<sup>2</sup>)). Disappearance of caged rapamycin and appearance of demethyl-rapamycin (i.e. rapamycin with OH at C7) were followed by HPLC (Zorbax- SB-C18 acetonitrile/water 70/30 3.5 mL/min, detected at 254 nm) and ESI (demethyl-rapamycin) ESI-MS:(C<sub>50</sub>H<sub>77</sub>NO<sub>13</sub>Na)(MNa<sup>+</sup>), calcd: 922.5287 found: 922.5293. UV-Vis (MeOH)  $\lambda_{\max}$  266, 275, 288

**DNA/RNA preparation**—The bicistronic plasmid pSP-(CAG)<sub>33</sub>-FF-HCV-Ren-p(A)<sub>51</sub> was a kind gift from Jerry Pelletier<sup>12,11</sup>. The plasmid was linearized by digestion with BamHI. The transcription reaction contained ribonucleotides from NEB (0.5 mM ATP, 0.5 mM CTP, 0.5 mM UTP, 0.1 mM GTP), 0.5 mM m<sup>7</sup>G(5')ppp(5')G (Ambion), 100 U RNase inhibitor (BioShop), 10  $\mu$ L 10X transcription buffer, 150 U SP6 polymerase (NEB), 3  $\mu$ g linearized pSP-(CAG)<sub>33</sub>-FF-HCV-Ren-p(A)<sub>51</sub> and water to 100  $\mu$ L. The reaction was incubated at 40°C for 2 hours, following which 6  $\mu$ L of RNase-free DNase was added and the mixture incubated a further 15 minutes at 37°C. For coupled transcription/translation reactions in rabbit reticulocyte lysate control Firefly luciferase DNA was used as supplied by the manufacturer.

### ***In vitro* translation reactions**

*In vitro* translations in rabbit reticulocyte lysate were performed according to the manufacturer's recommendations (Promega). *In vitro* translations in Krebs extracts were performed as described previously<sup>11, 12, 26</sup>. Translation reaction contained 7  $\mu$ L Krebs-2 cell extract, 50 ng RNA, 0.625–10  $\mu$ g 4E-BP peptide and was made up to a final volume of 10  $\mu$ L with 25 mM HEPES, pH7.5. Reactions were incubated at 30°C for 1 hour and terminated with the addition of 20  $\mu$ L of ice-cold PBS. Three  $\mu$ L of reaction mix was added to 25  $\mu$ L luciferase reagent from the Dual-Luciferase<sup>®</sup> reporter system (Promega) to quantify firefly luciferase translation and 25  $\mu$ L of Stop & Glo<sup>®</sup> Reagent to quantify Renilla luciferase.

### **HeLa cell studies**

Cell lines were purchased from the American Type Culture Collection (Manassas, VA). Cells were cultured in DMEM, supplemented with 10% fetal bovine serum (FBS) and 100 units/mL gentamicin at 37°C and 5% CO<sub>2</sub> in 75-cm<sup>2</sup> flasks. Cells were passaged by 0.25% Trypsin-EDTA when they reached ~80% confluence. Rapamycin and caged rapamycin stock solution were prepared in MeOH/water 50/50 then diluted in water so that volumes of 20–50  $\mu$ L of each sample was added to the cell culture well (final concentration 20–50 nM). For uncaging experiments samples were irradiated for 1 min using a 365 nm LED (Opto Technology, Inc., Wheeling, IL, Model OTLH-0480-UV (365 nm, ~20 mW)). Cells were then incubated with drug for 1 h then washed with 1 mL PBS followed by 0.3 mL SDS gel loading buffer. This procedure caused detaching of the cells as a slurry, which was then boiled for 6 min and frozen. Samples (30  $\mu$ L) were then applied to a 10% SDS polyacrylamide gel, then transferred to a nitrocellulose membrane (Protran, Perkin-Elmer). Membranes were blocked in 5% nonfat milk in TBS containing 0.1% Tween 20 and probed with the appropriate primary and secondary antibodies (phospho-S6K1 (Thr389), from Cell Signalling, phospho-S6 (Ser240/244) also from Cell Signalling, and beta-actin, from Sigma) at 4°C overnight. Immunoreactive proteins were visualized using enhanced chemiluminescence (Perkin-Elmer).

## Results and Discussion

### (i) DEAC-caged anisomycin

Anisomycin (**1**) is a cell permeable natural product that inhibits protein synthesis by binding to the peptidyl transferase site of the ribosome<sup>27, 28</sup>. Atomic resolution structures of the antibiotic in complex with the large ribosomal subunit indicate that bulky substituents on the amino group of anisomycin will severely inhibit binding<sup>28</sup>. Dore, Schumann and colleagues reported anisomycin derivatives in which the amino group was caged with either dimethoxynitrobenzyl (DMNB) (**2**) or bromohydroxycoumarin (BHC) (**3**) derivatives. Both compounds were shown to be effective caged inhibitors of protein synthesis with uncaging at 365 nm ( $\lambda_{\text{max}}$  are 350 and 373 nm respectively). Here we extend these studies by replacing the BHC group with diethylaminocoumarin moiety (**4**). While undergoing analogous photochemistry to BHC, the DEAC group has longer wavelength absorption ( $\lambda_{\text{max}}$  395 with significant absorbance to 420 nm, compared to  $\lambda_{\text{max}}$  373 nm for BHC) and a significantly higher molar extinction coefficient (~20,000 vs. 14,500 M<sup>-1</sup>cm<sup>-1</sup>). In addition, quantum yields for uncaging as high as 0.3 have been reported<sup>21, 29–31</sup>. Because an integrated 405 nm laser line that can be used for uncaging is becoming a common feature of a range of optical microscopes used for neuroimaging<sup>32, 33</sup>, a caged anisomycin derivative that could be activated effectively with this light source may prove practically useful.

DEAC-caged coumarin (**4**) was synthesized via oxidation of 7-(diethylamino)-4-methyl-2H-chromen-2-one with selenium dioxide as described<sup>21</sup> followed by coupling to anisomycin using *p*-nitrophenylchloroformate. Uncaging was tested using an HPLC assay (see methods) and using an *in vitro* translation assay. Translation was performed using rabbit reticulocyte lysate coupled transcription translation system using firefly luciferase DNA as template. Translational activity is measured by the amount of luciferase produced, which can be assayed accurately as relative light units produced under a standard set of conditions. Caged anisomycin was either uncaged immediately prior to adding to lysate or uncaged *in situ* with a 405 nm LED (20 mW/cm<sup>2</sup> radiant flux). Absorbance by the hemoglobin in the lysate resulted in longer half lives for uncaging *in situ*. The transcription/translation reactions were incubated for a further 1 h at 30°C after uncaging before assaying for luciferase activity. Very large changes (3 orders of magnitude) in translation rates were observed upon uncaging DEAC-anisomycin (Fig. 2).

Effective applied concentrations and light exposure times for use in living cells will require optimization in specific systems since maximal localization of the effect will require release of sufficient anisomycin to cause inhibition but not enough that diffusion leads to inhibitory concentrations outside the zone of interest. DEAC caged anisomycin provides an easy-to-use starting point for probing the role of local translation in the nervous system.

### (ii) Caged 4E-BP peptide for the inhibition of cap-dependent translation initiation

In most cases translation initiation is the rate limiting step in protein synthesis<sup>34</sup>. Translation initiation in eukaryotes can be cap-dependent requiring the presence of the m<sup>7</sup>GpppN cap structure (where “m” represents a methyl group and “N” is any nucleotide) at the 5' end of the messenger (m)RNA. Conversely, in specific instances ribosomes can assemble at an IRES (internal ribosome entry site) sequence in the mRNA<sup>36–38</sup> to initiate cap-independent translation. Local control of the mode of translation initiation has been proposed to play a roles in neurohormone secretion<sup>8</sup>, amyloid precursor protein production<sup>39</sup>, and FGF-2 production during brain development<sup>40</sup>.

The primary mechanism for regulating cap-dependent translation initiation is via binding of the 4E-BP proteins to the cap-binding translation initiation factor eIF4E. Three 4E-BPs have been identified (4E-BP1, 4E-BP2, 4E-BP3) together with the related proteins cup, maskin

and neuroguidin<sup>41–44</sup>. These proteins appear to act as competitive inhibitors of eIF4G binding to eIF4E<sup>41, 42</sup>. All 4E-BPs share with eIF4G a consensus eIF4E binding sequence. The sequence is shown below, numbered from the consensus Tyr at position zero. The symbols: b, X, f,  $\phi$  and PO4 represent partially conserved hydrophobic, any residue, partially conserved phenylalanine, conserved hydrophobic and phosphorylation site respectively.

Peptides corresponding to eIF4E binding sequences from 4E-BP1, 4E-BP2, and eIF4G have been shown to directly interact with purified recombinant eIF4E *in vitro*<sup>13, 45</sup> with affinities ranging from 10–100 nM. These peptides have also been reported to inhibit *in vitro* translation in cell lysates<sup>46</sup>. The effectiveness of 4E-BP1 peptides as translation initiation inhibitors *in vivo* has also been tested by microinjection of peptides into sea urchin embryos where dramatic effects on maturation were observed consistent with peptide inhibition of cap-dependent translation initiation<sup>47</sup>.

An effective means for developing photo-control of cap-dependent translation initiation would therefore be to develop a caged 4E-BP analogue. Although small molecule inhibitors of the 4E/4G interaction are under development<sup>12, 13</sup>, the affinity and selectivity of these does not yet match the native peptide sequences. For cell-based studies of local translation where photochemical tools will be applied locally over relatively short time scales, there is no requirement for tools to withstand the gut or the bloodstream, factors that limit the use of peptides broadly in drug development.

Substitution of the conserved Tyr (Y0) and Leu residues (L5) is known to severely inhibit binding of 4E-BPs to eIF4E<sup>45</sup>. This effect can be understood in structural terms because X-ray crystal data show both conserved residues make extensive contacts with the eIF4E protein<sup>48, 49</sup>. Figure 3 shows a close up view of the interactions between Tyr0 and eIF4E. Caging this Tyr residue is expected to lead to severe steric clashes between the peptide and the protein, so that peptide binding is prevented.

We prepared Fmoc-Tyr-DMNB and incorporated it into an extended 4E-BP peptide analogue (caged 4E-BP, Table I). Starting with the 4E-BP1 sequence (for which a K<sub>d</sub> of <50 nM has been measured with purified eIF4E<sup>48</sup>) we replaced the GluCys dipeptide sequence with AibAib and we removed potential phosphorylation sites (Ser11, Thr14). The AibAib unit promotes helical backbone conformations<sup>50</sup> thereby preorganizing the peptide into the bound conformation to enhance affinity. Removing phosphorylation sites eliminates the possibility that inhibitory effects of the 4E-BP analogues will be modified by the activity of kinases or phosphatases.

To test the ability of the caged 4E-BP peptide to photo-control cap-dependent translation, we prepared bicistronic mRNAs containing a capped transcript for firefly luciferase together with a Renilla luciferase transcript under control of an IRES sequences<sup>12</sup> (Fig. 4). Since firefly and Renilla luciferase enzymes use different substrates, they can be assayed together. Comparing the ratio of firefly luciferase to Renilla luciferase activity provides a direct measure of the relative rates of cap-dependent vs. cap-independent (IRES mediated) translation *in vitro*<sup>12</sup>. We carried out *in vitro* translation reactions in Krebs ascites lysates using this bicistronic RNA in the presence of different amount of 4E-BP peptides. The Krebs lysate has been found to more faithfully reproduce the cap-dependent translation initiation process as compared to the rabbit reticulocyte system<sup>26</sup>,

Figure 5 shows results obtained using *in vitro* translations in Krebs lysates. Irradiation with 365 nm light for 30s produced uncaged 4E-BP peptide which showed identical activity to pure synthetic 4E-BP peptide (Fig. 5) and more than an order of magnitude stronger inhibition of cap-dependent translation than the caged peptide. This result demonstrates that

the Tyr0 site is indeed an effective site for caging. Even more effective caging may be obtained with a bulkier caging group such as a coumarin derivative<sup>51</sup> or the nitrodibenzofuran compound recently reported by Momotake et al.<sup>52</sup>.

In order to be used for probing the role for cap-dependent versus cap-independent inhibition of translation in a cellular setting, caged 4E-BP peptides would have to be microinjected<sup>47</sup> or loaded via cell-uptake sequences. A variety of such sequences can be appended to the peptide during synthesis. Indeed Herbert et al have reported 4E-BP peptides bearing penetratin cell uptake sequences to be active in human lung fibroblast cells in culture.<sup>45</sup>

### (iii) Caged rapamycin for the inhibition of mTORC1

4E-BP activity is posttranslationally regulated via phosphorylation<sup>53</sup>. Upstream of 4E-BP is the central regulatory kinase mTORC1<sup>42</sup>. mTORC1 integrates the input from multiple pathways such as those triggered by insulin and growth factors<sup>54</sup>. mTORC1 phosphorylates S6K1 and this stimulates the subsequent phosphorylation of S6K1 by PDK1. Active S6K1 can in turn stimulate the initiation of protein synthesis through activation of S6 Ribosomal protein (a component of the ribosome) and other components of the translational machinery<sup>55</sup>. Translation may also be regulated in other ways including pathways involving ERK and p38 MAPK signalling<sup>56, 57</sup>. For instance, ARC synthesis during LTP consolidation in the dentate gyrus appears to be controlled via ERK-MNK signalling rather than via mTORC1<sup>9</sup>. A tool for the local control of mTORC1 would enable determination of the role of mTORC1 in local translation in variety of settings.

mTORC1 is known to be specifically inhibited by the membrane-permeable natural product rapamycin<sup>58</sup>. Rapamycin acts by binding to FKBP ( $K_d = 0.5$  nM) and this complex binds to and inhibits mTORC1<sup>25</sup>. A large medicinal chemistry patent literature describes numerous chemical modifications of rapamycin and their activities. One face of the rapamycin molecule interacts with FKBP and another face (called the effector domain) interacts with mTORC1<sup>58, 59</sup>. Detailed structural information is available for complexes of rapamycin with FKBP and for the ternary complex FKBP-rapamycin-mTOR<sup>59, 60</sup>. An examination of the X-ray crystal structure of the complex of FKBP/rapamycin with mTOR shows the position of the C7 methoxy group of rapamycin directly exposed to the mTOR interface (Fig. 6). Thus, introduction of a bulky caging group here is expected to effectively block mTORC1 activation

Luengo et al discovered that the methoxy position at C7 could be selectively substituted in a mild acid catalyzed process<sup>25</sup>. This remarkable transformation presumably results from the participation of the adjacent triene unit. Using this acid catalyzed substitution reaction we introduced a DMNB group at the C7 position of rapamycin (Fig. 7). We opted to use the DMNB group since (i) the dimethoxynitrobenzyl alcohol undergoes the acid catalyzed substitution reaction easily (ii) it provides sufficient steric bulk for caging and (iii) it undergoes uncaging at a wavelength (365 nm) that does not overlap significantly with the triene unit or rapamycin (near 280 nm). Uncaging is expected to produce 7-hydroxy rapamycin rather than native rapamycin. This compound has been reported to be active<sup>61</sup>, presumably because it retains the favourable interactions of rapamycin with its protein partners and does not introduce any steric hindrance.

Cell-based activity assays of this DMNB-caged rapamycin analog were carried out using established assays<sup>62, 63</sup>. HeLa cells were incubated with either vehicle, native rapamycin, DMNB-caged rapamycin or UV irradiated DMNB-caged rapamycin. Inhibition of mTORC1 was assayed by probing for changes in S6 and S6K phosphorylation levels via Western blot (Fig. 8). Caging was observed to block rapamycin activity very effectively since >10-fold differences in phospho-S6 were observed (Fig. 8(a), lane D vs. F). Importantly, near native

levels of activity were restored upon uncaging indicating that DMNB-caged rapamycin behaves as designed.

An NBDF caged rapamycin could be produced by an analogous synthetic route. The larger size of the NBDF group may lead to even great differences between caged and uncaged derivatives. In addition, the NDBF group is expected to show better two-photon uncaging properties than the DMNB-caged rapamycin<sup>52</sup>. While coumarin derivatives such as diethylaminocoumarin are appealing for longer wavelength uncaging, they have been reported to be ineffective for caging alcohols directly<sup>29</sup>. Instead a 7-hydroxy rapamycin derivative would have to be caged as a coumarin carbonate. Alternatively, Wosnick et al have reported that coumarins may be used to cage thiols directly<sup>64</sup>. Thus, a caged C7 mercapto rapamycin may be envisaged. All these derivatives are expected to be membrane permeable based on their similarity to numerous other rapamycin derivatives<sup>58</sup>. We therefore anticipate that they will be of direct use in experiments aimed at uncovering the role of mTORC1 in local translation.

## Summary

We have reported the successful caging of three compounds, anisomycin, 4E-BP and rapamycin, with well-defined roles in the molecular mechanisms of translation. The sites for caging and the choice of caging group lead in each case to a compound that shows a substantial (10–1000 times) difference in activity upon optical activation. These compounds or related derivatives, when optimized for particular applications may prove useful for probing the roles and mechanisms of local translation in the nervous systems of animal models.

## Acknowledgments


We would like to thank the Canadian Institutes for Health Research and the NIH for financial support of this work.

## References


1. Bramham CR, Wells DG. *Nat Rev Neurosci.* 2007; 8:776. [PubMed: 17848965]
2. Pfeiffer BE, Huber KM. *J Neurosci.* 2006; 26:7147. [PubMed: 16822970]
3. Schuman EM, Dynes JL, Steward O. *J Neurosci.* 2006; 26:7143. [PubMed: 16822969]
4. Banko JL, Klann E. *Prog Brain Res.* 2008; 169:59. [PubMed: 18394468]
5. Klann E, Dever TE. *Nat Rev Neurosci.* 2004; 5:931. [PubMed: 15550948]
6. Govindarajan A, Kelleher RJ, Tonegawa S. *Nat Rev Neurosci.* 2006; 7:575. [PubMed: 16791146]
7. Bourne J, Harris KM. *Curr Opin Neurobiol.* 2007; 17:381. [PubMed: 17498943]
8. Wayne NL, Lee W, Michel S, Dyer J, Sossin WS. *Biol Reprod.* 2004; 70:277. [PubMed: 14522824]
9. Panja D, Dagyte G, Bidinosti M, Wibrand K, Kristiansen AM, Sonenberg N, Bramham CR. *J Biol Chem.* 2009; 284:31498. [PubMed: 19755425]
10. Janzen DM, Geballe AP. *Cold Spring Harb Symp Quant Biol.* 2001; 66:459. [PubMed: 12762048]
11. Novac O, Guenier AS, Pelletier J. *Nucleic Acids Res.* 2004; 32:902. [PubMed: 14769948]
12. Cencic R, Robert F, Pelletier J. *Methods Enzymol.* 2007; 431:269. [PubMed: 17923239]
13. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA, Wagner G. *Cell.* 2007; 128:257. [PubMed: 17254965]
14. Sutton MA, Ito HT, Cressy P, Kempf C, Woo JC, Schuman EM. *Cell.* 2006; 125:785. [PubMed: 16713568]
15. Banko JL, Hou L, Poulin F, Sonenberg N, Klann E. *J Neurosci.* 2006; 26:2167. [PubMed: 16495443]

16. Costa-Mattioli M, Gobert D, Harding H, Herdy B, Azzi M, Bruno M, Bidinosti M, Ben Mamou C, Marcinkiewicz E, Yoshida M, Imataka H, Cuello AC, Seidah N, Sossin W, Lacaille JC, Ron D, Nader K, Sonenberg N. *Nature*. 2005; 436:1166. [PubMed: 16121183]
17. Nakashiba T, Young JZ, McHugh TJ, Buhl DL, Tonegawa S. *Science*. 2008; 319:1260. [PubMed: 18218862]
18. Ellis-Davies GC. *Nat Methods*. 2007; 4:619. [PubMed: 17664946]
19. Tanaka J, Horiike Y, Matsuzaki M, Miyazaki T, Ellis-Davies GC, Kasai H. *Science*. 2008; 319:1683. [PubMed: 18309046]
20. Goard M, Aakalu G, Fedoryak OD, Quinonez C, St Julien J, Poteet SJ, Schuman EM, Dore TM. *Chem Biol*. 2005; 12:685. [PubMed: 15975514]
21. Shembekar VR, Chen Y, Carpenter BK, Hess GP. *Biochemistry*. 2005; 44:7107. [PubMed: 15882049]
22. Wang Q, Dai Z, Cahill SM, Blumenstein M, Lawrence DS. *J Am Chem Soc*. 2006; 128:14016. [PubMed: 17061870]
23. Fletscher CA. *Organic Syntheses*. 1953; 33:65.
24. Wilcox M, Viola RW, Johnson KW, Billington AP, Carpenter BK, Mccray JA, Guzikowski AP, Hess GP. *J Org Chem*. 1990; 55:1585.
25. Luengo JI, Yamashita DS, Dunnington D, Beck AK, Rozamus LW, Yen HK, Bossard MJ, Levy MA, Hand A, Newman-Tarr T, et al. *Chem Biol*. 1995; 2:471. [PubMed: 9383449]
26. Svitkin YV, Sonenberg N. *Methods Enzymol*. 2007; 429:53. [PubMed: 17913619]
27. Hansen JL, Moore PB, Steitz TA. *J Mol Biol*. 2003; 330:1061. [PubMed: 12860128]
28. Blaha G, Gurel G, Schroeder SJ, Moore PB, Steitz TA. *J Mol Biol*. 2008; 379:505. [PubMed: 18455733]
29. Furuta, T. *Dynamic studies in biology: Phototriggers, photoswitches and caged biomolecules*. Goeldner, M.; Givens, R., editors. Wiley-VCH; Weinheim: 2005. p. 29
30. Shembekar VR, Chen Y, Carpenter BK, Hess GP. *Biochemistry*. 2007; 46:5479. [PubMed: 17425336]
31. Hagen V, Frings S, Wiesner B, Helm S, Kaupp UB, Bendig J. *Chembiochem*. 2003; 4:434. [PubMed: 12740815]
32. Lutz C, Otis TS, DeSars V, Charpak S, DiGregorio DA, Emiliani V. *Nat Methods*. 2008; 5:821. [PubMed: 19160517]
33. Olympus website 2009.
34. Gandin V, Miluzio A, Barbieri AM, Beugnet A, Kiyokawa H, Marchisio PC, Biffo S. *Nature*. 2008; 455:684. [PubMed: 18784653]
35. Gebauer F, Hentze MW. *Nat Rev Mol Cell Biol*. 2004; 5:827. [PubMed: 15459663]
36. Pelletier J, Sonenberg N. *Nature*. 1988; 334:320. [PubMed: 2839775]
37. Jackson RJ. *Biochem Soc Trans*. 2005; 33:1231. [PubMed: 16246087]
38. Filbin ME, Kieft JS. *Curr Opin Struct Biol*. 2009; 19:267. [PubMed: 19362464]
39. Beaudoin ME, Poirel VJ, Krushel LA. *Nucleic Acids Res*. 2008; 36:6835. [PubMed: 18953033]
40. Audigier S, Guiramand J, Prado-Lourenco L, Conte C, Gonzalez-Herrera IG, Cohen-Solal C, Recasens M, Prats AC. *RNA*. 2008; 14:1852. [PubMed: 18676616]
41. Lee VH, Healy T, Fonseca BD, Hayashi A, Proud CG. *FEBS J*. 2008; 275:2185. [PubMed: 18384376]
42. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. *Oncogene*. 2006; 25:6416. [PubMed: 17041626]
43. Jung MY, Lorenz L, Richter JD. *Mol Cell Biol*. 2006; 26:4277. [PubMed: 16705177]
44. Macdonald PM. *Curr Biol*. 2004; 14:R282. [PubMed: 15062123]
45. Herbert TP, Fahraeus R, Prescott A, Lane DP, Proud CG. *Curr Biol*. 2000; 10:793. [PubMed: 10898981]
46. Fletcher CM, McGuire AM, Gingras AC, Li H, Matsuo H, Sonenberg N, Wagner G. *Biochemistry*. 1998; 37:9. [PubMed: 9453748]


47. Salaun P, Boulben S, Mulner-Lorillon O, Belle R, Sonenberg N, Morales J, Cormier P. *J Cell Sci.* 2005; 118:1385. [PubMed: 15769855]
48. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. *Mol Cell.* 1999; 3:707. [PubMed: 10394359]
49. Tomoo K, Matsushita Y, Fujisaki H, Abiko F, Shen X, Taniguchi T, Miyagawa H, Kitamura K, Miura K, Ishida T. *Biochim Biophys Acta.* 2005; 1753:191. [PubMed: 16271312]
50. Mahalakshmi R, Balaram P. *Methods Mol Biol.* 2006; 340:71. [PubMed: 16957333]
51. Hagen V, Dekowski B, Kotzur N, Lechler R, Wiesner B, Briand B, Beyermann M. *Chemistry.* 2008; 14:1621. [PubMed: 18046693]
52. Momotake A, Lindegger N, Niggli E, Barsotti RJ, Ellis-Davies GC. *Nat Methods.* 2006; 3:35. [PubMed: 16369551]
53. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. *Genes Dev.* 2001; 15:2852. [PubMed: 11691836]
54. Hay N, Sonenberg N. *Genes Dev.* 2004; 18:1926. [PubMed: 15314020]
55. Kapp LD, Lorsch JR. *Annu Rev Biochem.* 2004; 73:657. [PubMed: 15189156]
56. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J. *J Biol Chem.* 2007; 282:14056. [PubMed: 17360704]
57. Proud CG. *Biochem J.* 2007; 403:217. [PubMed: 17376031]
58. Hartford CM, Ratain MJ. *Clin Pharmacol Ther.* 2007; 82:381. [PubMed: 17728765]
59. Choi J, Chen J, Schreiber SL, Clardy J. *Science.* 1996; 273:239. [PubMed: 8662507]
60. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. *J Mol Biol.* 1993; 229:105. [PubMed: 7678431]
61. Guadiana, MA.; Truesdell, S. USA Patent; WO 9606847. 1996. p. 21
62. Gingras AC, Raught B, Sonenberg N. *Prog Mol Subcell Biol.* 2001; 27:143. [PubMed: 11575159]
63. Raught B, Gingras AC, Sonenberg N. *Proc Natl Acad Sci USA.* 2001; 98:7037. [PubMed: 11416184]
64. Wosnick JH, Shoichet MS. *Chem Mater.* 2008; 20:55.




**Figure 1.** Structures of anisomycin (**1**), DMNB caged anisomycin (**2**), BHC-caged anisomycin (**3**) and DEAC caged anisomycin (**4**).




**Figure 2.** Measured luciferase activity (relative light units) (Note log scale). The final concentration of caged anisomycin in the translation assays was 80, 8 and 0.8  $\mu\text{M}$ . Dark gray bars are caged, light gray bars are uncaged (after exposure to a 356 nm LED for 10 s). The 8  $\mu\text{M}$  concentration provides three orders of magnitude greater inhibition after uncaging.




**Figure 3.** Structure of the 4E-BP1 peptide (cyan) bound to the eIF4E protein (gray surface). The essential Tyr(0) is labelled and the site of attachment for the caging group circled. The image is based on the X-ray data of Marcotrigiano et al<sup>48</sup>(PDB code 1EJ4). Figure prepared using Pymol.




**Figure 4.** Structure of DMNB-caged Tyr (b) structure of bicistronic construct for analysis of cap-dependent translation.




**Figure 5.** Inhibition of cap-dependent translation as measured by the ratio of firefly to Renilla luciferase activity in Krebs ascites extracts. Increasing amounts of caged (●), irradiated (caged, irradiated for 60 s)(○), and native 4E-BP peptides (△) were added to the reactions.



**Figure 6.** Rapamycin/FKBP/mTORC1 ternary complex. The 7-methoxy substituent of rapamycin (circled) points directly at mTORC1 (ribbon).



**Figure 7.** Synthesis of DMNB caged rapamycin. (i) trifluoroacetic acid in dichloromethane (ii) DMNB alcohol



**Figure 8.** Western blots for phospho-S6 (a) and phospho-S6K (b)(actin serves as an internal control for total protein concentration). A: control, B: vehicle, C: 50 nM rapamycin, D: 20 nM rapamycin, E: 50 nM caged rapamycin, F: 20 nM caged rapamycin, G: 50 nM uncaged (+UV) rapamycin, H: 20 nM uncaged (+UV).

Table I

Consensus 4E binding sequence and 4EBP1

<i>Position</i>	-3	-2	-1	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
<i>Consensus</i>	R/K	b	X	Y	X	X	X	f	L	φ	X	X	X	X	PO4	X	X	X
<i>4E-BP1</i>	R	I	I	Y	D	R	K	F	L	M	E	C	R	N	S	P	V	T
<i>Caged-P4E-BP</i>	R	I	I	Y	D	R	K	F	L	M	Aib	Aib	R	N	A	P	V	A
	P	G	G	A	R	P	G	G	A	R	P	K	A	K	A	P	A	P